Illumina, Inc. $750 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Illumina, Inc. of $750 million aggregate principal amount of its 0.0%…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Zoetis Inc. $1.5 Billion Senior Notes Offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $300 million aggregate principal amount of its floating-rate senior notes…
Davis Polk Advises ViewRay, Inc. on Its $172.5 Million Follow-On Common Stock Offering
Davis Polk advised ViewRay, Inc. in connection with its $172.5 million SEC-registered follow-on offering of 18,648,649 shares of common stock, which included the full exercise of the…
NeoGenomics Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the approximately $125 million public offering of common stock of…
REGENXBIO Inc. $175.5 Million Common Stock Offering
Davis Polk advised the representatives of the underwriters in connection with the $175.5 million offering of 2,700,000 shares of common stock of REGENXBIO Inc. The common stock is listed on…
BeiGene Ltd. HK$7.08 Billion (US$903 Million) Public Offering on the Hong Kong Stock Exchange
Davis Polk advised the underwriters and the joint global coordinators in the public offering of BeiGene, Ltd. on the Hong Kong Stock Exchange. The gross proceeds from the offering…
Davis Polk Advises Pernix on Private Exchange Offers
Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with separate private exchange offers for its existing 12% senior secured notes due 2020 held by certain holders for new…
Davis Polk Advises AC Immune SA on Its $117.5 Million Follow-On Public Offering and Subscription Rights Offerings
Davis Polk advised AC Immune SA in connection with its $117.5 million U.S. follow-on public offering. AC Immune sold 8,500,000 of its newly issued common shares and subscription rights…
Teladoc, Inc. $348.9 Million Common Stock Offering
Davis Polk advised the underwriter in connection with a $348.9 million SEC-registered offering of 5,263,740 shares of common stock of Teladoc, Inc., consisting of 5,000,000 shares sold by…
Constellation Pharmaceuticals Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public offering of common stock of Constellation Pharmaceuticals, Inc. The…